Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-23T16:27:10.618Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacogenetic profiles of young danish individuals with and without severe mental disorders

Published online by Cambridge University Press:  13 August 2021

C. Lunenburg ,
J. Thirstrup  and
C. Gasse
C. Lunenburg
Affiliation:
Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark
J. Thirstrup
Affiliation:
Department Of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark
C. Gasse*
Affiliation:
Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Centre For Integrated Register-based Research, Aarhus University, Aarhus, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. PGx guidelines for psychotropic drugs are available (PGx drugs). By executing PGx testing in a prospective or pre-emptive setting, dose adjustments or even change of treatment type can be applied prior to start of therapy to patients who carry a specific geno- or phenotype (i.e. actionable geno- or phenotypes). By doing so, increased efficacy of therapy or reduced risk of adverse events of treatment can be accomplished. In Denmark, broad implementation of PGx is currently still low.

Objectives

The aim of this study is to classify the PGx profiles of Danish individuals with and without severe mental disorders (SMD), to be used in follow-up studies investigating PGx and drug outcomes.

Methods

This study made use of imputed genotyping data of the Danish iPSYCH sample, which includes 77,639 young individuals born between 1981-2005, with or without a diagnosis of one or more of five selected SMD (i.e. depression, attention-deficit/hyperactivity disorder, autism, bipolar disorder and schizophrenia). We investigated a panel of 48 genetic variants with known PGx applications (part of the U-PGx consortium, a Horizon2020 funded project on clinical relevant PGx in the EU).

Results

Imputed data contains over 11 million SNPs of 77,639 individuals.

Conclusions

We expect results in the end of 2020.

Disclosure

We thank the iPSYCH consortium, in specific the iPSYCH PI’s (Merete Nordentoft, Anders Børglum, Preben B. Mortensen, Ole Mors, Thomas Werge and David M. Hougaard). The iPSYCH project is funded by the Lundbeck Foundation Denmark and the universities and un

Keywords

genotypephenotypePharmacogenetics
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S144 - S145
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.